QQ客服 官方微博 反馈留言

	Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study
	Wu, Yi-Long; Zhou, Caicun; Lu, Shun; Qin, Shukui; Pan, Hongming; Wu, Gang; Cheng, Ying; Liu, Xiaoqing; Han, Baohui; Zhu, Yunzhong
刊名	LUNG CANCER
	2019
卷号	130页码:18-24
关键词	Chemotherapy EGFR Asian Non small cell lung cancer Erlotinib
ISSN号	0169-5002
URL标识	查看原文
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/2826793
专题	西安交通大学
推荐引用方式 GB/T 7714	Wu, Yi-Long,Zhou, Caicun,Lu, Shun,et al. Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study[J]. LUNG CANCER,2019,130:18-24.
APA	Wu, Yi-Long.,Zhou, Caicun.,Lu, Shun.,Qin, Shukui.,Pan, Hongming.,...&Jiang, Guoliang.(2019).Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study.LUNG CANCER,130,18-24.
MLA	Wu, Yi-Long,et al."Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study".LUNG CANCER 130(2019):18-24.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。